[Inclusion body myositis]

Presse Med. 1996 Jun 15;25(21):985-8.
[Article in French]

Abstract

Inclusion body myositis has been recently recognized as a clinical entity although its exact definition remains uncertain. Initially considered to be an inflammatory dermatomyositis, inclusion body myositis can actually take on three specific forms: disseminated muscle atrophy and weakness, pseudopolymyositis, or pseudo-degenerative disease. Inclusion body myositis is different from non-inflammatory neuromuscular diseases with vacuoles. Abnormal deposits are seen within the muscle fiber may contain amyloid substance, beta-amyloid precursor, ubiquitin, antichymotrypsin, protein tau, apolipoprotein E and even prions. The signification of these deposits is unknown. Deletions in mitochondrial DNA have been demonstrated but do not appear to play a causal role. More and more hereditary forms are being recognized and certain may be related to an abnormality in chromosome 9.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Amyloid beta-Peptides / biosynthesis*
  • Autoimmune Diseases / complications*
  • Female
  • Humans
  • Male
  • Myositis, Inclusion Body / complications*
  • Myositis, Inclusion Body / genetics
  • Myositis, Inclusion Body / metabolism
  • Myositis, Inclusion Body / pathology
  • Prions / biosynthesis
  • Ubiquitins / biosynthesis*
  • alpha 1-Antichymotrypsin / biosynthesis
  • tau Proteins / biosynthesis

Substances

  • Amyloid beta-Peptides
  • Prions
  • Ubiquitins
  • alpha 1-Antichymotrypsin
  • tau Proteins